Abstract
Recurrent disease after apparent ‘cure’ of primary tumors is a common factor that contributes to cancer-associated mortality. A new study suggests that an inflammatory cytokine signature may provide a clinical indication of emergent recurrent disease and, accordingly, may suggest how to select and deliver therapy targeted against the secondary tumor (pages 1625–1631).
Original language | English (US) |
---|---|
Pages (from-to) | 1569-1570 |
Number of pages | 2 |
Journal | Nature medicine |
Volume | 19 |
Issue number | 12 |
DOIs | |
State | Published - Dec 2013 |
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)